Skip to main content

Professor Dominic Behan – University of Reading

Show access keys

Professor Dominic Behan

Responsibilities

Visiting Professor

Professor Dominic Behan

Professor Behan received his Ph.D. under Professor Phil Lowry at the University of Reading, that resulted in the purification of corticotropin releasing factor (CRF)-binding protein (CRF-BP), a key modulator of the CRF family of neuropeptides that are the principle mediators of the body's response to stress. The gene was subsequently cloned in collaboration with Professor Wylie Vale and colleagues at the Salk Institute in California. In 1997, Dr. Behan co-founded Arena Pharmaceuticals Inc., a company focused of discovering drugs targeting a broad class of signaling molecules called G-protein coupled receptors (GPCRs). Arena developed a robust pipeline of GPCR modulators, the first of which, BELVIQ® (lorcaserin HCl), was approved by the FDA in 2012 for chronic weight management. He now acts as Chair of the Arena Scientific Advisory Board, was included in the PharmaVOICE 100 list, serves on the scientific advisory board of Keystone and received a higher doctorate degree (D.Sc.) from the University of Reading where he was also appointed as Visiting Professor. Dr. Behan now serves as CEO of Sentia Medical Sciences Inc., a company whose vision is to bring to fruition several decades of academic research to achieve translational drug candidacy, by developing a new class of drug candidates called astressins for the treatment of stress-related diseases.

We use Javascript to improve your experience on reading.ac.uk, but it looks like yours is turned off. Everything will still work, but it is even more beautiful with Javascript in action. Find out more about why and how to turn it back on here.
We also use cookies to improve your time on the site, for more information please see our cookie policy.

Back to top